WASHINGTON – In a significant shift within the Food and Drug Administration (FDA), Dr. Marty Makary has announced his resignation after a tumultuous year in charge of the agency. His departure comes amid ongoing criticisms from various sectors, including health industry executives, anti-abortion activists, and vaping lobbyists, many of whom are aligned with former President Donald Trump.
Makary’s resignation, confirmed by a White House official, follows a challenging tenure during which he struggled to gain the confidence of FDA staff. This official, who wished to remain anonymous, indicated that Kyle Diamantas, the agency’s chief for foods, will assume the role of acting commissioner. Notably, Diamantas has personal ties to Donald Trump Jr., highlighting the political connections surrounding this leadership change.
Dr. Makary, a surgeon and health researcher, rose to prominence among Republicans as a vocal critic of COVID-19 health measures, frequently appearing on Fox News. His outspoken nature, however, did not translate into effective management of the FDA’s complex bureaucracy. His tenure was marked by mass layoffs, leadership instability, and controversies where scientific principles appeared to be compromised by political pressures, including those from Health Secretary Robert F. Kennedy Jr.
The role of FDA commissioner is inherently challenging, requiring a delicate balance between scientific rigor and political demands. Makary faced intense pressure from Trump and other Republicans to expedite approvals, while simultaneously addressing Kennedy’s scrutiny of vaccine and drug safety. This balancing act proved problematic, as many senior officials either resigned or were ousted during his first year.
Despite his efforts to streamline drug approvals—initiatives that included reducing study requirements and integrating artificial intelligence—Makary’s tenure was overshadowed by internal conflicts. Many pharmaceutical executives highlighted that predictability and consistency in FDA decisions are paramount, and the turmoil within the agency created significant challenges for drugmakers and patients alike.
Furthermore, Makary faced backlash from various interest groups. Anti-abortion advocates criticized him for delays in reviewing the abortion pill mifepristone, while vaping industry representatives claimed he obstructed the approval of essential products, including flavored e-cigarettes. Although the FDA recently authorized new fruit-flavored products, it was too late to salvage Makary’s position.
The path forward for the FDA remains uncertain. A permanent replacement for the commissioner will require nomination by Trump and subsequent confirmation by the Senate. With the political landscape continually shifting, the future of many initiatives introduced under Makary’s leadership hangs in the balance, as they may be easily overturned by his successors.
As the FDA embarks on this new chapter, the agency’s ability to navigate the complex interplay of science, politics, and public health will be more crucial than ever. The priorities set by the incoming leadership will shape the landscape of health regulation in the United States, particularly as the nation continues to grapple with the implications of the COVID-19 pandemic and emerging health challenges.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
